Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors
Conditions: Small-cell Lung Cancer; Soft Tissue Sarcoma; Triple-negative Breast Cancer; Ovarian Cancer Intervention: Drug: Tinostamustine (EDO-S101) Sponsor: Mundipharma-EDO GmbH Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials